Fatty acid amide hydrolase (FAAH) is a membrane-associated enzyme that catalyzes the hydrolysis of several endogenous bioactive lipids, including anandamide (AEA), N-palmitoylethanolamine (PEA), oleamide, and N-oleoylethanolamine (OEA). These fatty acid amides participate in many physiological activities such as analgesia, anxiety, sleep modulation, antiinflammatory responses, and appetite suppression. Because FAAH plays an essential role in controlling the tone and activity of these endogenous bioactive lipids, this enzyme has been implicated to be a drug target for the therapeutic management of pain, anxiety, and other disorders. In an effort to discover FAAH inhibitors, the authors have previously reported the development of a novel fluorescent assay using purified FAAH microsomes as an enzyme source and a fluorogenic substrate, arachidonyl 7-amino, 4-methyl coumarin amide (AAMCA). Herein, the authors have adapted this assay to a high-throughput format and have screened a large library of small organic compounds, identifying a number of novel FAAH inhibitors. These data further verify that this fluorescent assay is sufficiently robust, efficient, and low-cost for the identification of FAAH inhibitory molecules and open this class of enzymes for therapeutic exploration. (Journal of Biomolecular Screening 2006:519-527) 
INTRODUCTION
F ATTY ACID AMIDE HYDROLASE (FAAH) is an enzyme responsible for the catabolism of a number of primary and secondary fatty acid amide bioactive lipids, 1-3 including the natural analgesic anandamide (AEA), the sleepinducing substance oleamide, the anti-inflammatory compound N-palmitoylethanolamine (PEA), and the appetite-suppressing agent N-oleoylethanolamine (OEA). [4] [5] [6] [7] [8] Several lines of evidence demonstrate that FAAH plays an essential role in controlling the physiological tone and activity of these endogenous bioactive lipids. FAAH knockout mice show highly elevated endogenous levels of anandamide, PEA, and OEA in the brain and spinal cord. 9, 10 These mice experience reduced pain sensations due to a CB1 receptor-dependent hypoalgesia, 11, 12 display antiinflammatory phenotypes, 10 and have modulated sleep episodes. 13 Consistent with these observations, FAAH inhibitors have been shown to increase the levels of endocannabinoids in the brain and produce analgesic and anxiolytic effects in rodents. 14, 15 These findings demonstrate the central role of FAAH in regulating endocannabinoid signaling in vivo and suggest that this enzyme may represent a novel target for the treatment of pain, as well as other neuronal disorders such as anxiety and depression.
The FAAH protein contains an amidase signature domain that is responsible for its catalytic activity. Previously, sitedirected mutagenesis studies have identified the conserved residue Ser-241 of the amidase signature domain as the catalytic nucleophile and Lys-142 as an acid/base catalyst. 16, 17 Consistent with this notion, several serine hydrolase inhibitors, such as fluorophosphonate and phenylmethylsulfonyl fluoride (PMSF), potently inhibit FAAH by covalently modifying the serine residue in its active site. 18, 19 Several assays for measuring FAAH activity have previously been described. [19] [20] [21] [22] [23] [24] However, almost all of these assays employ radioactive substrates. In these cases, the AEA or oleamide is labeled with 3 H or 14 C at its arachidonoyl, oleadonyl, or ethanolamide moiety. The FAAH activity is then measured by the rate of release of the radioactive products after hydrolysis. The critical step in these assays is to separate the radioisotopelabeled products from the intact, nonhydrolyzed substrates, using organic solvent (chloroform/methanol) extraction, chromatography, or charcoal adsorption. 25 These procedures make the radioactive assays much less applicable to robotic systems and thus are not suitable for the high-throughput screening (HTS) for FAAH inhibitors.
Recently, we reported the development of a novel nonradioactive assay based on a fluorogenic substrate for FAAH. 26 This fluorescent assay avoids the use of potentially hazardous radioactive compounds and organic solvents, such as chloroform and methanol. This assay is simple, sensitive, and specific; has a good signal-to-noise ratio; and is compatible with high-throughput formats. Herein, we describe an application of this fluorescent assay to a robotic platform for the HTS of a large number of compounds to identify inhibitors of FAAH. Using this platform, we screened more than 450,000 general chemical compounds and discovered a number of highly potent inhibitors of FAAH with IC 50 values in low nM range.
MATERIALS AND METHODS

Reagents
Arachidonyl 7-amino, 4-methyl coumarin amide (AAMCA) was synthesized by Biomol (Plymouth Meeting, PA). The AAMCA was analyzed by liquid chromatography/mass spectrometry (LC/MS), and its purity was found to be over 90%. Anandamide, [ethanolamine 1-3 H] (60 Ci/mmol) was purchased from American Radiolabled Chemicals (St. Louis, MO). All culture media and reagents were purchased from Invitrogen (Carlsbad, CA). 7-Amino, 4-methyl coumarin (AMC), methotrexate and fatty acids-free bovine serum albumin (BSA), and other chemicals were from Sigma-Aldrich (St. Louis, MO).
Establishment of Chinese hamster ovary cell line stably expressing FAAH
As described previously, 26 Chinese hamster ovary (CHO)-DukX/A2 cells were transfected with linearized pHTOP-6His-FAAH DNA using the Lipofectamine 2000 reagent (Invitrogen). Forty-eight hours posttransfection, the cells were split and selected in medium containing various concentrations of methotrexate (20 nM, 50 nM, or 100 nM) for 2 to 3 weeks. Colonies were then picked and cultured in MEM-α medium containing 10% dialyzed fetal calf serum, 100 µg/mL penicillin, 100 µg/mL streptomycin, 1 mg/mL G418, 2 mM L-glutamine, and 15 mM HEPES (pH 7.4) with the appropriate methotrexate concentration. For evaluating FAAH protein expression in each clone, cells were harvested, lysed, and analyzed by Western blot with the anti-His antibody (Penta-His, Qiagen). Clones with the highest FAAH expression were chosen for further large-scale culture.
Large-scale cell culture and microsome preparation
CHO-DukX-A2 cells stably expressing the human FAAH were cultured in suspension at 37 ο C with 5% CO 2 , in MEM-α medium containing 10% dialyzed fetal bovine serum, 15 mM HEPES (pH 7.3), 1 mg/mL G418, and 20 nM methotrexate. After approximately 5 days in culture, cells from 35L medium were pelleted by centrifugation at 2000 rpm for 10 min. Cell pellets were then washed twice with phosphate-buffered saline (PBS) and resuspended in 200 mL ice-cold buffer containing 50 mM HEPES (pH 7.4), 1 mM EDTA, 20 mM NaCl, and 10 tablets of "Complete EDTA-free" Protease inhibitor cocktail (Roche, Indianapolis, IN). The cell suspension was then passed through a French Pressure Cell Press (SIM-Aminco Spectronic Instruments, Rochester, NY) twice at a pressure of 10,000 psi at 4 ο C. The cell lysate was then centrifuged at 1000g for 20 min in a GSA rotor in a RC5C centrifuge (Sorvall Instruments, Thermo Electron, Asheville, NC) to remove cell debris. The supernatant was then centrifuged at 20,000g for 40 min in a GSA rotor, and the pellet was discarded. The supernatant was further centrifuged at 150,000g for 1 h in a Type 45 Ti rotor in L8-M Ultracentrifuge (Beckman, Fullerton, CA). The pellet contained the microsomal fraction and was resuspended in a 50-mL assay buffer (50 mM HEPES [pH 7.4], 1 mM EDTA, 0.1% fatty acid-free BSA). The protein concentration in the microsome preparation was determined using the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA), and the microsomes were diluted with assay buffer to a protein concentration of 4 mg/mL and aliquoted into small fractions (5 mL) and frozen at -80 ο C until use.
FAAH fluorescent assay for HTS
The assays were performed in 384-well black plates (Nalge Nunc International, Rochester, NY) in a total volume of 25 µL per well. Before the assay, solutions of AAMCA (5 µM) and FAAH microsome (27.7 µg/mL) were prepared in the assay buffer consisting of 50 mM HEPES (pH 7.4), 1 mM EDTA, and 1.4 mg/mL BSA (0.1% BSA final), and screening compounds were dissolved in 100% DMSO at a concentration of 37.5 µg/mL. During the assay, 2 µL of compound was added first to each well of the plates using a PE Minitrack pipettor. Then, 5 µL of the 5-µM AAMCA substrate and 18 µL of the 27.7-µg/mL FAAH microsomes were loaded to each well by a PE Flexdrop dispenser. The final compound concentration in the assay is 3 µg/mL, and the final DMSO concentration in assay is 8%. The assay plates were incubated for 3 h at room temperature (~25 ο C) and then read on a PE Envision plate reader at λ ex = 355 nM and λ em = 460 nM.
Data analysis
The percent inhibition of FAAH activity was calculated by referencing the relative fluorescence unit (RFU) of each compound well to the median RFU of the plate.
Percent inhibition = 100 -(RFU of compound well × 100/median RFU of the whole plate).
The IC 50 values were calculated using GraphPad Prism 3.02 or IDBS XLFit 4.0 program based on a sigmoidal doseresponse equation. The screening window coefficient (Z´ factor) was calculated according to the following equation as previous described 27 :
where σ c+ and σ c− are standard deviations of positive and negative controls, and µ c+ and µ c− are means of positive and negative controls, respectively.
To calculate the activity cutoff value, we assumed that the response of inactive compounds was normally distributed. The mean of the percent inhibition for all samples was estimated with the median value at 50th percentile of the distribution. The standard deviation of the percent inhibition for all compounds tested was then estimated based on the interquartile range (IQR):
Active compounds were defined as those samples that were 3 SD above the median percent inhibition.
Assay of [ 3 H]-anandamide hydrolysis by FAAH microsomes
Microsomal fractions (0.5 µg/assay) prepared from CHO cells expressing human FAAH were incubated with the indicated concentrations of anandamide, [1-3 H-ethanolamine] for 30 min at 25 ο C in buffer containing 50 mM HEPES (pH 7.4), 1 mM EDTA, and 0.1% BSA. The reaction was terminated by the addition of 2 volumes of chloroform/methanol (1:1, v/v). The samples were vortexed and centrifuged at 1000g for 3 min. The aqueous phase, containing [ 3 H]ethanolamine, was collected and measured by liquid scintillation counting. Results are presented as the mean ± SE of triplicate measurements from at least 2 independent experiments. The observed rate constants (apparent K m ) were calculated using GraphPad Prism 3.02 based on the Michaelis-Menten (1 site binding hyperbola) equation
RESULTS
Automation and adaptation of assay in high-throughput format
We recently reported a fluorescent assay to measure the hydrolase activity of FAAH. 26 This assay uses microsomes expressing the FAAH protein as an enzymatic source and AAMCA as a substrate that can be degraded by FAAH to produce arachidonic acid and AMC, a highly fluorescent molecule (λ ex = 355 nm, λ em = 460 nm) ( Fig. 1) . This assay has been shown to be specific for FAAH because microsomes prepared from cells expressing the inactive FAAH-S241A mutant or vector alone had no significant activity on the hydrolysis of AAMCA. 26 To adapt this assay to a high-throughput format for compound screening, conditions of the assay, such as concentration of substrate, amount of microsomes, and time course of reaction, were further optimized using the substrate and large-scale microsomes prepared for the HTS campaign. It is advantageous to screen compounds at a substrate concentration that is below the K m to identify inhibitors that compete with the substrate for the enzyme's active site. It is also desirable to use the lowest concentrations of substrate and enzyme that yield a reliable, reproducible signal. As shown in Figure 2 , AAMCA hydrolysis by the FAAH microsomes followed apparent Michaelis-Menten kinetics with an observed K m of 5.3 µM and V max of 20 pmol/min/mg microsome protein, respectively ( Fig. 2A) . Assays using 1 µM AAMCA substrate, which is well below the K m , gave a robust fluorescent signal that was linear with the concentration of FAAH microsomes (Fig. 2B) . The FAAH microsomes at 0.5 to 10 µg per well produced an acceptable AAMCA hydrolysis rate with a strong fluorescent signal, and the rate of increase in fluorescence remained in the linear part of the substrate conversion curve for up to 3 h ( Fig. 2C) . Based on these results, FAAH microsomes at a concentration of 0.5 µg per well, AAMCA at 1 µM, and a reaction time of 3 h were chosen for the screen. This protocol provides an appropriate balance between maximizing the ratio of signal to noise of the assay and minimizing the use of reagents required for the HTS. Validation assays were run on a fully automated system using the HTS protocol. Each 384-well plate contained the following controls: substrate only, substrate plus enzyme, and 8 doses of a positive control compound (WAY-473). As shown in Table 1 , results indicated excellent well-to-well, plate-to-plate, and day-to-day reproducibility. The Z´ values ranged from 0.589 to 0.808, and the IC 50 values of WAY-473 were from 11.51 nM to 18.82 nM. These data indicated that the assay is sufficiently robust and validate it for HTS.
HTS and data analysis
Approximately 457,000 chemically diverse compounds, including 35,700 natural products samples, were screened at a single concentration of 3 µg/mL in 384-well plates on a fully automated system. To monitor the quality of the screening, control plates that contained substrate only, substrate plus microsomes, and a dose-response curve of WAY-473 were included at the beginning, the middle, and the end of each screening batch every day. We evaluated the quality of the HTS campaign by 2 parameters, the values of IC 50 of the positive compound WAY-473 and the Z´ factors from the control plates in every run. As shown in Figure 3 , the IC 50 values of WAY-473 in all runs ranged from 4.5 to 21 nM. This narrow range of IC 50 values demonstrates the quality of the screening data. The Z´ factors from all runs ranged from 0.45 to 0.84 and are shown in Figure 4 . A few screenings had low Z´ (below 0.45) or flat inhibition curves of WAY-473 and were therefore rejected. All plates in that run were repeated to produce satisfactory Z factor or IC 50 values.
A normal distribution around zero was observed when the frequency was plotted versus the percent inhibition data of all compounds, indicating that most compounds were inactive ( Fig. 5) . To determine the cutoff threshold for primary hits, the median and the SD of percent inhibition for all samples tested were estimated to be 0 and 12.48, respectively, based on the IQR. The primary hits were defined as those samples that have an inhibition of 37.5% or greater, 3 standard deviations above the median percentage inhibition. Based on this value, approximately 23,000 hits were identified from the primary screen, representing an approximate 5% hit rate. These primary hits were then rescreened in a 5-dose titration (0.04, 0.11, 0.33, 1, and 3 µg/mL) in triplicate using the same protocol. The hit criterion for this 5-dose titration screening was defined to be larger than or equal to 37.4% inhibition at either 1-µg/mL or 3-µg/mL doses of compounds. This multidose titration screen reduced the hit numbers from 23,000 to about 5000, and the final hit rate was estimated to be 1.1%, which is within the normal range of HTS screens using automated enzymatic and biochemical assays. Compounds that quench the fluorescence of AMC would appear as false positives in the screen. Therefore, a counterscreen in which the ability of compounds (3 µg/mL) to inhibit AMC fluorescence was run in triplicate and the 8 compounds that inhibited the AMC signal by more than 20% were discarded. The 5036 confirmed hits were first triaged to a group of 3725 compounds by removing compounds containing chemical liabilities/electrophilic groups (i.e., aldehydes, oximes, α-bromoketones, etc.). To focus on the compounds with the best 5-point dose titration graphs, the 3725 compounds were clustered into self-organizing maps (SOM bins) where compounds The cutoff threshold of activity was calculated as 37.5%, the value of 3 SD from the median. Compounds with greater than 37.5% inhibition of FAAH activity were counted as primary hits.
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with similar-shaped dose-response curves were clustered together ( Fig. 6) . Compounds in bins 2, 3, 5, and 8 were removed from future consideration, as they appeared to be less efficacious/potent than the other bins. Compounds in bins 6 and 9 showed good dose titration responses from 0.04 µg/mL to 1.0 µg/mL, followed by a decrease in activity at 3.0 µg/mL, which is likely to reflect compound insolubility. In summary, the compounds in bins 1, 4, 6, 7, 9, 10, 11, and 12 were kept for future investigation, and this SOM bin analysis prioritized a set of 2745 compounds from the initial 3725 hits.
Follow-up of HTS hits
The IC 50 values of 2745 representative hit compounds from the HTS were further determined manually in an FAAH fluorescent assay using the standard protocol (1 µM AAMCA substrate, 0.5 µg/assay microsome). A total of 514 compounds showed a typical sigmoidal semilogarithmic curve with IC 50 values less than or equal to 1 µM. After further evaluation of chemical structures and additional criteria such as integrity, purity, and logP value, 335 compounds were selected as secondary hits. Figure 7A shows the dose-dependent inhibition of FAAH activity by 4 example compounds from the 336 hits. The IC 50 values of these 4 compounds are distributed from 1 nM to 77 nM. Consistently, these compounds inhibited FAAH with a similar potency in the radioactive anandamide hydrolysis assay (Fig. 7B) .
DISCUSSION
HTS is an efficient and rapid means of identifying, from a large collection of compounds, a subset of hits that interact with a target of interest. Thus, the discovery of novel FAAH inhibitors from a large compound library requires an assay system well suited to HTS applications. Unfortunately, most assays previously available for measuring FAAH activity are unsuitable for HTS because they are radioactive based and/or use hazardous organic solvents. [20] [21] [22] 28 These potential hazards and the difficulties associated with the separation of radiolabeled products become major hurdles for the application of these assays to HTS. Recently, the use of charcoal instead of solvents to separate the radioactive products has been described. 25 Despite the authors' claim that this assay could be applied in HTS format, the filtering step to remove the charcoal used to separate the radioactive ethanolamine from the unhydrolyzed AEA in the reaction makes this assay more costly in terms of time and labor. Most recently, a spectrophotometric assay of FAAH was described using oleamide as a substrate. 29 This assay appears to be less suitable for HTS because it is a dual-enzyme assay that uses the L-glutamate dehydrogenase-catalyzed NADH/NAD + -coupled reaction to measure the production of ammonia that is released from oleamide by FAAH. It is therefore likely to identify inhibitors for both enzymes. FAAH is an integral membrane protein predominantly expressed in the microsomal fraction of cells. 19 Analysis of the FAAH protein sequence and structure identified the α18 and α19 (amino acids 410-438) hydrophobic motifs, which integrate into membrane leaflets. 30 Interestingly, these α18 and α19 motifs, positioned as a cap on the active site of FAAH, suggest that the membrane association of the FAAH may be required for the stability and enzymatic activity of the protein. 31 The interaction between the enzyme and membrane may also be important for efficient rates of substrate hydrolysis and product release. Hence, it is advantageous to use this microsomal assay, which maintains the FAAH protein in its native membrane environment.
The apparent K m and V max values (5.3 µM and 20 pmol/min/ mg microsome protein) observed using reagents prepared for the HTS campaign differ from the values (0.48 µM and 58 pmol/min/mg microsome protein) we reported previously. 26 This discrepancy may reflect the variability in the reagents used and conditions of assays, such as the reaction temperature. Furthermore, the AAMCA affinity (K m ) that was measured may not represent the true binding affinity of the substrate for the enzyme because AAMCA is a lipophilic substrate that could form micelles and fuse with the microsomal membrane before being hydrolyzed by FAAH. 26 Similar phenomena have been observed in other assays using lipophilic substrates. 32 The K m of AEA for FAAH varies widely between reports, with values ranging from 0.8 to 180 µM in the literature. 33 The pH of the assay buffer is critical for FAAH activity. It has been reported that FAAH activity is pH dependent, with maximal activity between pH 7.5 and 9. 19, 23 Consistent with these observations, we found that AAMCA hydrolysis by FAAH microsomes showed highest activity between pH 7.5 and 9.5. There was a sharp decline in activity beyond this pH range. The FAAH activity at pH 7 remained by approximately 50% of the maximal activity (unpublished data). Thus, any changes of pH values of the assay buffer may significantly contribute to the variability of the Z´ values during the HTS.
Our previous studies showed that the inclusion of fat-free serum albumin in the reaction buffer facilitated AAMCA hydrolysis in the reaction by binding the arachidonic acid released from substrate hydrolysis. Arachidonic acid has been reported to inhibit FAAH activity. 34 The inclusion of BSA in the assay also helps the solubility of the AAMCA substrate and prevents the nonspecific binding of AAMCA to the wall of the assay plate. The optimal concentration of BSA in the reaction was determined to be 0.1%; higher BSA concentrations lead to increased air bubbles in the process of liquid handling.
As shown in our previous report, this assay can tolerate DMSO up at least to 10% (v/v) of the final assay volume. 26 This relatively high concentration of DMSO makes the compound screening more feasible because all of our compounds are dissolved in 100% DMSO. The 8% of DMSO in the assay solution dramatically assists the solubility of hydrophobic compounds in the aqueous assay environment. In many cases, the precipitation of hydrophobic compounds from the assay solution during screening is a serious problem. In summary, the assay described here is well suited to measure the hydrolase activity of FAAH. This robust and cost-effective assay is easily adapted to a 384-well platform and exhibits a satisfactory screening window coefficient (Z´ factor). Using this assay, we have screened more than 457,000 small organic compounds to identify inhibitors of FAAH. Of these compounds, 5036 compounds were shown to significantly inhibit FAAH activity. Using a series of filters, this number of compounds was reduced to 336 potent hits with an IC 50 less than 1 µM, which represent novel leads. Additional studies of these leads will be carried out to investigate their mode of inhibition of FAAH. Furthermore, the in vivo activity of these compounds will be assessed to determine if an increase in anandamide levels in the brain and thus endocannabinoid signaling has therapeutic potential for the treatment of pain and other disorders.
CONCLUSIONS
We described here an application of a recently published novel microsome-based fluorescent assay to screen for FAAH inhibitors in a 384-well protocol. This fully automated, homogeneous assay was employed in an HTS of 457,000 compounds with a throughput of 40,000 data points per day. The high quality of the data obtained using this assay is reflected by the high Z´ factor values and highly reproducible IC 50 values of the control compound. This low-cost assay was successful in identifying a set of potent FAAH inhibitors, a critical step in the development of novel therapeutic agents against FAAH.
